AI assistant
Sending…
Moderna, Inc. — Director's Dealing 2022
Apr 1, 2022
30610_dirs_2022-04-01_73a3d457-ab32-49c7-90f4-2e267f1aa748.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2022-03-30
Reporting Person: Andres Juan (See remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-03-30 | Common Stock | M | 2000 | $14.22 | Acquired | 11069 | Direct |
| 2022-03-30 | Common Stock | S | 2000 | $182.79 | Disposed | 9069 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-03-30 | Stock Option (Right to Buy) | $14.22 | M | 2000 | Disposed | 2028-02-28 | Common Stock (2000) | Direct |
Footnotes
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021.
F2: This option is fully vested and exercisable.
More from Moderna, Inc.
Regulatory Filings
2026
May 11
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Feb 25
Regulatory Filings
2026
Feb 23
Annual Report
2026
Feb 20
Director's Dealing
2026
Feb 13
Director's Dealing
2026
Feb 13